“…Ten studies reported separate outcomes for CS patients, two reported separate outcomes of patients with GCM, and two reported outcomes for both diseases. The overall 1-, 5-, or 10-year survival rates for patients with either CS [ 6 – 8 , 20 , 21 , 23 , 25 , 27 , 30 , 31 ] or GCM [ 14 , 21 , 24 , 31 ] after HTx were described in 12 publications. One- or 5-year acute cellular rejection rates after HTx for either CS [ 8 , 21 , 27 , 30 , 31 ] or GCM [ 14 , 21 , 24 , 31 ], as well as disease recurrence at any time post-HTx in patients with CS [ 6 , 8 , 20 , 21 , 28 , 30 , 31 ] or GCM [ 21 , 31 ], were reported in seven studies each.…”